Posts by: Margarida Azevedo, MSc

Margarida Azevedo, MSc

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

March 6, 2020March 6, 2020

Innovation Designs Plan for Phase 2 Brilacidin Trial for Ulcerative Colitis

News

The planned brilacidin Phase 2 trial will be conducted in two parts and test several therapy doses, against a placebo, to determine the safety and effectiveness of the investigational oral ... Read more

June 18, 2018June 18, 2018

FDA OKs for Use Noninvasive Stool Sample Test to Help Diagnose IBD

News

Bühlmann Laboratories has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its noninvasive fCAL Elisa test, which uses a stool sample to help diagnose inflammatory bowel disease (IBD). fCAL ... Read more

June 13, 2018June 13, 2018

Remicade Eases Anxiety, Improves Quality of Life for Some Crohn’s Patients, China Study Finds

News

Remicade (infliximab) significantly benefitted the mental health of patients newly diagnosed with Crohn’s disease who had responded to the treatment, improving their perceptions of their illness and quality of life, and lowering anxiety levels, a ... Read more

June 11, 2018June 11, 2018

Microbiotica and Genentech Partner to Study Microbiome Biomarkers and New IBD Therapies

News

Microbiotica, a company spun out of the Wellcome Sanger Institute, recently established a multiyear collaboration agreement with Genentech to discover, develop, and commercialize biomarkers, targets, and therapies for inflammatory bowel disease (IBD). ... Read more

May 30, 2018May 30, 2018

Thetis Awarded $1.9M NIH Grant to Advance TP-252 into Clinical Trials for Ulcerative Colitis

News

Thetis Pharmaceuticals recently received a $1.9 million fast-track Small Business Innovation Research grant from the National Institutes of Health (NIH) to help advance the development of TP-252, an investigational oral therapy for ulcerative ... Read more

May 25, 2018May 25, 2018

IBD Research Teams Invited to Apply for Rainin Foundation’s Synergy Awards

News

The Kenneth Rainin Foundation is now accepting proposals for its Synergy Awards program, which provides up to $300,000 to teams collaborating across disciplines to advance the study and understanding of ... Read more

May 23, 2018May 23, 2018

Projects Aim to Improve Decision-making, Communication Between IBD Patients, MDs

News

The Crohn’s and Colitis Foundation, the American Gastroenterological Association (AGA) and Pfizer recently presented the results of a request for proposals to devise interventions aimed at improving shared decision-making and ... Read more

April 4, 2018April 4, 2018

Daiichi Sankyo, Crohn’s & Colitis Foundation Launch Campaign About Iron Deficiency Anemia

News

Daiichi Sankyo and the Crohn’s & Colitis Foundation recently launched a new iron deficiency awareness campaign called Get Iron Informed. The campaign aims to educate people about iron deficiency anemia ... Read more

March 28, 2018March 28, 2018

FDA Approves Cimzia Label Update Essential for Childbearing Women with Inflammatory Diseases

News

The U.S. Food and Drug Administration (FDA) recently approved UCB’s request for a label update for Cimzia (certolizumab pegol) indicating low transfer levels of the medication from mother to child through ... Read more

March 23, 2018March 23, 2018

Artificial Sweetener Splenda Found to Worsen Symptoms of Crohn’s Disease in New Mouse Study

News

The artificial sweetener Splenda (sucralose maltodextrin) was recently found to worsen gut inflammation in mice with Crohn’s disease, while no effects were seen in mice without the condition. The investigation, ... Read more